Who
Diana McKenzie
Director
Company insider
Files Form 4 as: Director, MetLife; Director, agilon health; Director, Vertex Pharmaceuticals; Director, Change Healthcare.
In numbers
- Trades disclosed
- 121
- Buys
- 2
- Sells
- 0
- Bought
- $45K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 1 Nov 2018
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | $51K544 at $94.35 | filing |
| 8 Sep 2026filed 10 Sep 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | $15K157 at $95.50 | filing |
| 8 Sep 2026filed 10 Sep 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | $15K157 at $95.50 | filing |
| 16 Jun 2026filed 18 Jun 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | $51K587 at $87.40 | filing |
| 16 Jun 2026filed 18 Jun 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | $51K587 at $87.40 | filing |
| 9 Jun 2026filed 11 Jun 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | $14K169 at $85.57 | filing |
| 9 Jun 2026filed 11 Jun 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | $14K169 at $85.57 | filing |
| 2 Jun 2026filed 4 Jun 2026 | AGL agilon healthProviders & Facilities | SEC FORM 4 Code A | —2,133 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | AGL agilon healthProviders & Facilities | SEC FORM 4 Code A | —2,133 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —943 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —796 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —796 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —796 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —943 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —796 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | $51K721 at $71.17 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | $51K721 at $71.17 | filing |
| 10 Mar 2026filed 12 Mar 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | $13K189 at $70.60 | filing |
| 10 Mar 2026filed 12 Mar 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | $13K189 at $70.60 | filing |
| 2 Jan 2026filed 6 Jan 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | $51K639 at $80.32 | filing |
News
Analyzing Agilon Health (NYSE:AGL) and Fulgent Genetics (NASDAQ:FLGT)AGL · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Diana McKenzie; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.